Donate to Science & Enterprise

S&E on Mastodon

S&E on LinkedIn

S&E on Flipboard

Please share Science & Enterprise

Antibody/Gene Therapy Biotech Gains $138 Million in Early Funds

Adeno-associated virus

A developer of synthetic antibodies for neurodegenerative disorders delivered like gene therapies is raising €129 million ($US 138 million) in its first venture funding round. . . . → Read More: Antibody/Gene Therapy Biotech Gains $138 Million in Early Funds

Infographic – Digital Health Funding Continues Slide

Bar chart: Digital health venture funding by quarter, 2019 through 2023

Venture funding for digital health start-ups continued heading down in the third quarter of 2023, reaching low levels not seen in almost a decade. . . . → Read More: Infographic – Digital Health Funding Continues Slide

Life Science Incubator Gains $100M in Start-Up Funds

Raven in a tree

A new-business accelerator program, begun earlier this year to advance and commercialize biomedical research discoveries from academic labs, is receiving a $100 million founding grant. . . . → Read More: Life Science Incubator Gains $100M in Start-Up Funds

Merger to Form Programmable Nano-Medicines Company

Molecule model in an open hand

A life science venture investor is merging two of its biotechnology portfolio companies to form a single developer of nanoscale medications with programmable properties. . . . → Read More: Merger to Form Programmable Nano-Medicines Company

Organ Chip Devices to Model for Radiation Sickness

Organ on a chip

The U.S. government’s health preparedness agency awarded a contract with a university lab to explore organ models on chips to document effects of radiation sickness. . . . → Read More: Organ Chip Devices to Model for Radiation Sickness

Start-Up Adapts Crispr for Molecular Detection, Raises $40M

Crispr graphic

A new company is underway that says it adapts the gene editing technique Crispr to make detecting nucleic acid targets like DNA or RNA faster and simpler. . . . → Read More: Start-Up Adapts Crispr for Molecular Detection, Raises $40M

Infographic – Q3 Life Science Venture Funds Tick Up

Bar chart: U.S. life science venture funding by quarter, 2013 to 2023

Venture investments in U.S. life science and biotechnology start-ups in the third quarter of 2023 rose from the previous two quarters to reach pre-pandemic levels. . . . → Read More: Infographic – Q3 Life Science Venture Funds Tick Up

Longevity Science Group Spins-Off Biotech Start-Up

Naked mole rat on black background

An organization funding research on extending the human life span by preventing age-related diseases is founding its first biotechnology company. . . . → Read More: Longevity Science Group Spins-Off Biotech Start-Up

Collapsed Microbiome Biotech Sells Off Assets

Microbiome illustration

A developer of therapies addressing the body’s microbe communities is selling off key assets to another biotechnology company, after problems developed with its lead program. . . . → Read More: Collapsed Microbiome Biotech Sells Off Assets

Neuro Disease Biotech Gains $61M in Early Funds

Brain cell networks

A developer of treatments for Alzheimer’s disease that seeks to improve the condition of the brain’s support cells is raising £48 million ($US 61 million) in its first venture round. . . . → Read More: Neuro Disease Biotech Gains $61M in Early Funds